Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy

NCT03069703 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Invasive Pneumococcal Infection

Interventions

BIOLOGICAL: PCV13
BIOLOGICAL: PPV23
DRUG: Rituximab

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]